{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T06:03:07Z","timestamp":1790143387451,"version":"4.0.1"},"reference-count":44,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1016\/j.hoc.2013.11.003","type":"journal-article","created":{"date-parts":[[2014,1,18]],"date-time":"2014-01-18T17:51:28Z","timestamp":1390067488000},"page":"287-299","source":"Crossref","is-referenced-by-count":23,"title":["The Role of Adenosine Signaling in Sickle Cell Therapeutics"],"prefix":"10.1016","volume":"28","author":[{"given":"Joshua J.","family":"Field","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G.","family":"Nathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Linden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.hoc.2013.11.003_bib1","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1080\/mic.11.2.129.151","article-title":"The endothelial biology of sickle cell disease: inflammation and a chronic vasculopathy","volume":"11","author":"Hebbel","year":"2004","journal-title":"Microcirculation"},{"key":"10.1016\/j.hoc.2013.11.003_bib2","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1172\/JCI9225","article-title":"Hypoxia\/reoxygenation causes inflammatory response in transgenic sickle mice but not in normal mice","volume":"106","author":"Kaul","year":"2000","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.hoc.2013.11.003_bib3","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJM199107043250103","article-title":"Pain in sickle cell disease. rates and risk factors","volume":"325","author":"Platt","year":"1991","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2013.11.003_bib4","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1056\/NEJM199406093302303","article-title":"Mortality in sickle cell disease. Life expectancy and risk factors for early death","volume":"330","author":"Platt","year":"1994","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2013.11.003_bib5","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1182\/asheducation.V2012.1.271.3798318","article-title":"Emerging \u2018A\u2019 therapies in hemoglobinopathies: agonists, antagonists, antioxidants, and arginine","volume":"2012","author":"Vichinsky","year":"2012","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.hoc.2013.11.003_bib6","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1182\/asheducation-2009.1.62","article-title":"Advances in the use of hydroxyurea","author":"Ware","year":"2009","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.hoc.2013.11.003_bib7","first-page":"968","article-title":"Provider barriers to hydroxyurea use in adults with sickle cell disease: a survey of the Sickle Cell Disease Adult Provider Network","volume":"100","author":"Lanzkron","year":"2008","journal-title":"J\u00a0Natl Med Assoc"},{"key":"10.1016\/j.hoc.2013.11.003_bib8","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.bbmt.2008.06.005","article-title":"Paucity of HLA-identical unrelated donors for\u00a0African-Americans with hematologic malignancies: the need for new donor options","volume":"14","author":"Dew","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.hoc.2013.11.003_bib9","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1182\/blood-2009-02-205492","article-title":"NKT cells mediate pulmonary inflammation and dysfunction in murine sickle cell disease through production of IFN-gamma and CXCR3 chemokines","volume":"114","author":"Wallace","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2013.11.003_bib10","doi-asserted-by":"crossref","first-page":"5010","DOI":"10.1182\/blood-2010-06-290643","article-title":"Adenosine A2A receptors induced on iNKT and NK cells reduce pulmonary inflammation and injury in mice with sickle cell disease","volume":"116","author":"Wallace","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2013.11.003_bib11","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.1182\/blood-2012-11-465963","article-title":"Sickle cell vaso-occlusion causes activation of iNKT cells that is decreased by the adenosine A2A receptor agonist regadenoson","volume":"121","author":"Field","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2013.11.003_bib12","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/nm.2280","article-title":"Detrimental effects of adenosine signaling in sickle cell disease","volume":"17","author":"Zhang","year":"2011","journal-title":"Nat Med"},{"key":"10.1016\/j.hoc.2013.11.003_bib13","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1096\/fj.09-144147","article-title":"Increased adenosine contributes to penile fibrosis, a dangerous feature of priapism, via A2B adenosine receptor signaling","volume":"24","author":"Wen","year":"2010","journal-title":"FASEB J"},{"key":"10.1016\/j.hoc.2013.11.003_bib14","first-page":"3011","article-title":"Adenosine deaminase enzyme therapy prevents and reverses the heightened cavernosal relaxation in priapism","volume":"7","author":"Wen","year":"2010","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.hoc.2013.11.003_bib15","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1172\/JCI33467","article-title":"Excess adenosine in murine penile erectile tissues contributes to priapism via A2B adenosine receptor signaling","volume":"118","author":"Mi","year":"2008","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.hoc.2013.11.003_bib16","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/nrd1983","article-title":"Adenosine receptors as therapeutic targets","volume":"5","author":"Jacobson","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.hoc.2013.11.003_bib17","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/nrd2638","article-title":"Adenosine receptors: therapeutic aspects for inflammatory and immune diseases","volume":"7","author":"Hasko","year":"2008","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.hoc.2013.11.003_bib18","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1100\/tsw.2011.22","article-title":"Anti-inflammatory and immunosuppressive effects of the A2A adenosine receptor","volume":"11","author":"Milne","year":"2011","journal-title":"ScientificWorldJournal"},{"issue":"10","key":"10.1016\/j.hoc.2013.11.003_bib19","doi-asserted-by":"crossref","first-page":"e74664","DOI":"10.1371\/journal.pone.0074664","article-title":"NF-kB is activated in CD4+ iNKT cells by sickle cell disease and mediates rapid induction of adenosine A2A receptors","volume":"8","author":"Lin","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.hoc.2013.11.003_bib20","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1146\/annurev.immunol.18.1.621","article-title":"Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity","volume":"18","author":"Karin","year":"2000","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.hoc.2013.11.003_bib21","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4049\/jimmunol.173.1.21","article-title":"Cutting edge: physiologic attenuation of proinflammatory transcription by the Gs protein-coupled A2A adenosine receptor in\u00a0vivo","volume":"173","author":"Lukashev","year":"2004","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.hoc.2013.11.003_bib22","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1084\/jem.20061097","article-title":"Adenosine A2A receptor activation reduces hepatic ischemia reperfusion injury by inhibiting CD1d-dependent NKT cell activation","volume":"203","author":"Lappas","year":"2006","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.hoc.2013.11.003_bib23","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.coi.2008.03.018","article-title":"CD1d-restricted iNKT cells, the\u00a0\u2018Swiss-Army knife\u2019 of the immune system","volume":"20","author":"Matsuda","year":"2008","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.hoc.2013.11.003_bib24","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s00441-010-1023-3","article-title":"Invariant natural killer T cells: bridging innate and adaptive immunity","volume":"343","author":"Van Kaer","year":"2011","journal-title":"Cell Tissue Res"},{"key":"10.1016\/j.hoc.2013.11.003_bib25","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S1074-7613(00)80174-0","article-title":"Murine CD1d-restricted T cell recognition of cellular lipids","volume":"12","author":"Gumperz","year":"2000","journal-title":"Immunity"},{"key":"10.1016\/j.hoc.2013.11.003_bib26","doi-asserted-by":"crossref","first-page":"20490","DOI":"10.1073\/pnas.0710145104","article-title":"Modulation of human natural killer T cell ligands on TLR-mediated antigen-presenting cell activation","volume":"104","author":"Salio","year":"2007","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"key":"10.1016\/j.hoc.2013.11.003_bib27","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/nri854","article-title":"The unconventional lifestyle of NKT cells","volume":"2","author":"Kronenberg","year":"2002","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.hoc.2013.11.003_bib28","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2174\/187153007780832109","article-title":"CXCR3 axis: role in inflammatory bowel disease and its therapeutic implication","volume":"7","author":"Singh","year":"2007","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"10.1016\/j.hoc.2013.11.003_bib29","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.clim.2011.03.002","article-title":"Targeting iNKT cells for the treatment of sickle cell disease","volume":"140","author":"Field","year":"2011","journal-title":"Clin Immunol"},{"key":"10.1016\/j.hoc.2013.11.003_bib30","unstructured":"Astellas Pharma. Lexiscan [package insert]. Northbrook (IL): Astellas Pharma; 2009."},{"key":"10.1016\/j.hoc.2013.11.003_bib31","doi-asserted-by":"crossref","first-page":"337","DOI":"10.2147\/VHRM.S1798","article-title":"Regadenoson in the detection of coronary artery disease","volume":"4","author":"Buhr","year":"2008","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.hoc.2013.11.003_bib32","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.it.2009.04.001","article-title":"A2B adenosine receptors in immunity and inflammation","volume":"30","author":"Hask\u00f3","year":"2009","journal-title":"Trends Immunol"},{"key":"10.1016\/j.hoc.2013.11.003_bib33","doi-asserted-by":"crossref","first-page":"7726","DOI":"10.4049\/jimmunol.172.12.7726","article-title":"Adenosine-activated mast cells induce IgE synthesis by B lymphocytes: an A2B-mediated process involving Th2 cytokines IL-4 and IL-13 with implications for asthma","volume":"172","author":"Ryzhov","year":"2004","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.hoc.2013.11.003_bib34","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1365-2125.1983.tb01481.x","article-title":"Inhaled adenosine and guanosine on airway resistance in normal and asthmatic subjects","volume":"15","author":"Cushley","year":"1983","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.hoc.2013.11.003_bib35","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/sj.bjp.0706272","article-title":"The Quintiles Prize Lecture 2004. The identification of the adenosine A2B receptor as a novel therapeutic target in asthma","volume":"145","author":"Holgate","year":"2005","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.hoc.2013.11.003_bib36","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/bjp.2008.361","article-title":"Adenosine receptors and asthma in humans","volume":"155","author":"Wilson","year":"2008","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.hoc.2013.11.003_bib37","doi-asserted-by":"crossref","first-page":"G401","DOI":"10.1152\/ajpgi.00454.2007","article-title":"Purinergic receptors in gastrointestinal inflammation","volume":"294","author":"Kolachala","year":"2008","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.hoc.2013.11.003_bib38","first-page":"478","article-title":"Cyclic nucleotide signaling in cavernous smooth muscle","volume":"2","author":"Lin","year":"2005","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.hoc.2013.11.003_bib39","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0014-2999(01)01167-0","article-title":"Role of adenosine and P2 receptors in the\u00a0penile tumescence in anesthetized dogs","volume":"425","author":"Noto","year":"2001","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.hoc.2013.11.003_bib40","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1124\/jpet.106.107821","article-title":"Corpus cavernosum from men with vasculogenic impotence is partially resistant to adenosine relaxation due to endothelial A2B receptor dysfunction","volume":"319","author":"Faria","year":"2006","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.hoc.2013.11.003_bib41","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/nm0111-38","article-title":"Adenosine receptor crossroads in sickle cell disease","volume":"17","author":"Gladwin","year":"2011","journal-title":"Nat Med"},{"key":"10.1016\/j.hoc.2013.11.003_bib42","doi-asserted-by":"crossref","first-page":"679","DOI":"10.2174\/138920008786049249","article-title":"Measurement of the endogenous adenosine concentration in humans in\u00a0vivo: methodological considerations","volume":"9","author":"Ramakers","year":"2008","journal-title":"Curr Drug Metab"},{"key":"10.1016\/j.hoc.2013.11.003_bib43","doi-asserted-by":"crossref","first-page":"3524","DOI":"10.1182\/blood-2009-06-189209","article-title":"How I treat ADA deficiency","volume":"114","author":"Gaspar","year":"2009","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2013.11.003_bib44","doi-asserted-by":"crossref","DOI":"10.1038\/scibx.2011.62","article-title":"Two edges of sickle cell disease","volume":"4","author":"Haas","year":"2011","journal-title":"Science-Business eXchange"}],"updated-by":[{"DOI":"10.1016\/j.hoc.2014.12.002","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000}}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858813001901?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858813001901?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,14]],"date-time":"2020-08-14T09:39:49Z","timestamp":1597397989000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858813001901"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["S0889858813001901"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2013.11.003","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.hoc.2014.12.002","asserted-by":"object"}]},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2014,4]]}}}